Identification of PXR Activators from Uncaria Rhynchophylla (Gou Teng) and Uncaria Tomentosa (Cats Claw) [Articles]

Abstract

Uncaria rhynchophylla (Gou Teng) and Uncaria tomentosa (cat’s claw) are frequently used herbal supplements in Asia and America, respectively. Despite their common usage, information is limited regarding potential herb-drug interactions associated with Gou Teng and cat’s claw. The pregnane X receptor (PXR) is a ligand-dependent transcription factor that regulates cytochrome P450 3A4 (CYP3A4) expression and contributes to some known herb-drug interactions. A recent study found that Gou Teng induces CYP3A4 expression, but its mechanism is unknown. Cat’s claw has been determined as a PXR-activating herb, but the PXR activators in cat’s claw have not been identified. Using a genetically engineered PXR cell line, we found that the extracts of Gou Teng and cat’s claw can dose-dependently activate PXR and induce CYP3A4 expression. We next used a metabolomic approach to profile the chemical components in the extracts of Gou Teng and cat’s claw followed by screening for PXR activators. Four compounds, isocorynoxeine, rhynchophylline, isorhynchophylline, and corynoxeine, were identified as PXR activators from both Gou Teng and cat’s claw extracts. In addition, three more PXR activators were identified from the extracts of cat’s claw, including isopteropodine, pteropodine, and mitraphylline. All seven of these compounds showed the half-maximal effective concentration <10 µM for PXR activation. In summary, our work determined Gou Teng as a PXR-activating herb and discovered novel PXR activators from Gou Teng as well as cat’s claw.

SIGNIFICANCE STATEMENT This study’s data can be used to guide the safe use of Gou Teng and cat’s claw by avoiding PXR-mediated herb-drug interactions.

FootnotesReceived December 12, 2022.Accepted February 10, 2023.

This work was supported by National Institutes of Health National Center for Complementary and Integrative Health [Grant R21-AT011088] (to X.M.). This work was in part supported by National Institutes of Health National Institute of Allergy and Infectious Diseases [Grant R01-AI131983] (to X.M.) and National Institute of Diabetes and Digestive and Kidney Diseases [Grant R01-DK126875] (to X.M.).

There is no conflict of interest to state.

dx.doi.org/10.1124/dmd.122.001234.

Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics

留言 (0)

沒有登入
gif